Formulary

September 7, 2012

Web Version  |   Unsubscribe  |  Digital Edition  |  Share with a colleague

Facebook Like   Twitter Tweet

Today's Headlines

Mepolizumab effective in treating eosinophilic asthma

Mepolizumab significantly reduces asthma exacerbations in patients with severe eosinophilic asthma, according to a study published in the August 18 issue of The Lancet. » Full article

Intravenous aspirin plus alteplase effect on stroke

Early administration of intravenous aspirin, in addition to alteplase, does not improve functional outcome at 3 months for patients with acute ischemic stroke, but increases the risk of symptomatic intracranial hemorrhage, according to a study published online August 25 in The Lancet. » Full article

Smoking quit rate and community-based programs

Retail pharmacies' smoking cessation programs are effective in helping smokers quit, according to a study published in the September issue of The Annals of Pharmacotherapy. » Full article

Clinical trials moving to emerging countries

International pharmaceutical companies are increasingly out-sourcing clinical trials to countries in Asia, Latin America, and Eastern Europe, in an attempt to save time, money, and resources, according to a new report from GBI Research.
» Full article

CONTINUING EDUCATION

Enhancing immunization rates

As advocates of public health through immunization, pharmacists can build public awareness, identify patient needs, and provide vaccination services.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

EDITOR'S PICK

FDA user fee legislation speeds drug approvals, addresses shortages, counterfeits

The FDA Safety and Innovation Act, which President Obama recently signed into law, enables FDA to collect some $6 billion in fees over the next 5 years from pharmaceutical and medical device companies. But, challenges remain. » Full article

Survey

With recent healthcare reform preventive services legislation enacted, requiring payers to provide coverage of preventive medications, including contraceptives at no cost to patients, what do you anticipate will be the likely impact of this legislation?


a) Significant growth in pharmacy costs, overcome by more significant reduction in medical costs

b) Modest growth in pharmacy costs, overcome by more significant reduction in medical costs

c) A wash: Any growth in pharmacy costs offset by comparable reduction in medical costs

d) Modest growth in pharmacy costs, NOT offset by medical cost savings

e) Significant growth in pharmacy costs, NOT offset by medical cost savings

Respond here and see what your colleagues think too.


Want to see the results of our last survey regarding strategies to best curb prescription painkiller abuse? Click here.

 

Subscribe Now!

You must click here to continue receiving the Formulary News Capsule

Related Articles

FDA grants priority review to TB drug

New orphan drug for CML is approved

Late-stage prostate cancer treatment

Anticoagulants to prevent stroke in AF

RESOURCES

Drug Watch

Latest Clinical News

 
Powered by Modern Medicine Advanstar Medical Communications Group